HALOZYME THERAPEUTICS, INC. (HALO) Free cash flow 2016–2025
HALOZYME THERAPEUTICS, INC. (HALO) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$644.6MFY2025 · since FY2016: -$53.5M → $644.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $644.6M | +37.6% |
| FY2024 | $468.4M | +25.5% |
| FY2023 | $373.3M | +58.6% |
| FY2022 | $235.3M | -21.0% |
| FY2021 | $298.0M | +462.8% |
| FY2020 | $53.0M | +159.2% |
| FY2019 | -$89.5M | -65.2% |
| FY2018 | -$54.2M | -140.8% |
| FY2017 | $132.7M | +348.0% |
| FY2016 | -$53.5M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice